Recruiting
Phase 3

Serplulimab & Chemotherapy

Sponsor:

Shanghai Henlius Biotech

Code:

NCT05468489

Conditions

Extensive Stage Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Serplulimab + chemotherapy (carboplatin-etoposide)

Atezolizumab + chemotherapy (carboplatin-etoposide)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information